More about our sector?

this is your place

Data Scientist 4.0 – Bridging the World of Manufacturing and Data

Data Scientist 4.0 – Bridging the World of Manufacturing and Data

 

Since the announcement of the 4th Industrial Revolution in 2011, multitudes of emerging technologies have transpired around “Industry 4.0”.  Technologies such as digital twins, Industrial Internet of Things (IIoT), and cyber-physical systems have come into the scene as core elements, providing the necessary ingredients for a paradigm shift in manufacturing.  Technologies around predictive analytics and artificial intelligence are pioneering new approaches with many use cases including predictive maintenance, autonomous process optimization, and pattern recognition – used to identify potential failures in real-time.  Because of this, data science is becoming an invaluable discipline for our industry in order to transform information into knowledge.  As data scientists begin to play a fundamental role in the new way of understanding industrial and manufacturing activities, a new challenge appears: data engineers have to deal with unknown processes, procedures, operations, science and specific casuistries (where all of the potential answers lay).

Every industry requires different machine learning and deep learning systems.  The retail sector is very customer oriented and opportunities lie behind the buyer preferences and needs.  The natural language processing and media analytics are tools widely used to make attractive suggestions to the final consumer.  Fintech requirements are also different. Data scientists must adapt to specific algorithms for fraud detection, aggregation, and anomaly detection of tones of commercial transactions in real-time or for insurance policies based on a large variety of medical and health risk indicators.

 

 

The manufacturing activity for Industry 4.0 is even more complex. The pharmaceutical and biotech industries are a special case among the wide manufacturing spectrum. Medicine prerequisites like safety, quality, and efficacy must be validated before it goes to market. The linkage between health agencies and business requirements is a unique intersection that makes the pharma ecosystem special.  The reason being that human safeguard must always be the first priority.  When processes are designed and implemented in the factory, they are subject to strong quality controls based in many cases, on the assumption that the variability must be minimized.  This makes it difficult to validate operations that supply results based on algorithms like the random forest. However, some machine learning algorithms have been accepted by the European Pharmacopoeia as valid chemometric techniques for processing analytical data sets.

As we move forward, the Administration and the Regulatory Institutions are cautiously observing and establishing the first approach to the set of laws that must govern the data, processes, and the results obtained through AI algorithms. Thus, appears a new generation of data scientists and technological experts with a clear orientation for regulatory guidance, initiating the path to a commonly accepted approach to data management and data integrity. When results coming from AI algorithms are used in aeronautics, automotive, medical, and pharmaceutical activities with direct impact on people’s health, the full process must be surveilled and understood in order to grant the personal safety.

The unique characteristics in Industry 4.0 require that manufacturing specialists take care not only about the products being manufactured but also about the associated data and analytics offered as an added value to the distributed goods. The industrial data scientists 4.0 must know the algorithms to apply on top of the data ecosystem which requires future innovators to be multidisciplinary and specialized at the same time. They have a huge mission to satisfy the growing demand for data science services applied everywhere.

Melissa Villalobos

Sales and Marketing Coordinator

Bigfinite Announces Additions to Executive Team

Bigfinite, Inc. (Bigfinite), the leading manufacturing data analytics platform company for regulated industries, today announced that Brian Sweeney, Lawrence Baisch and Glenn Griffin have been added to the leadership team.
Crystal Black VP of Marketing

AI Algorithm Qualification

Pharmaceuticals and Biotech companies have no doubt that Artificial Intelligence (AI) is here to stay. Nonetheless, the opportunities AI technology offers are developing at a slow pace in a rather conservative manufacturing industry, aimed at managing production risks under controls that are subject to strong regulations. Fear of change? Risk aversion? Likely not.
Jordi Guitart VP of Artificial Intelligence

Bigfinite Announces Senior Leadership Additions

Bigfinite, Inc. (Bigfinite), the leading manufacturing data analytics platform company for regulated industries, today announced that John Vitalie has been named Chief Executive Officer (CEO) and has been elected to the Board of Directors. David Merino has been named Chief Financial Officer (CFO) of Bigfinite.

Why Biotech and Pharma Need GxP for their Digital Transformation Projects Now

Technological Enhancements with Principal Component Analysis Combined with Artificial Intelligence

Bigfinite Closes Series B Financing with Atlantic Bridge and Honeywell Ventures to Drive Disruption in Manufacturing Analytics

2019 Xavier University AI Summit Reflections – Two Industries Ready for Change

Now that the dust has settled from the Xavier University AI Summit and our team is back to business, we’ve had time to process some of the highlights and key takeaways from the exciting event.  In the past few years, there has been a significant increase in the implementation of digital technologies into various industries that subsequently impacted the way we live, travel, and do business.  From driverless cars to 24/7 customer support chatbots, innovation and technology continue to spiral upward and as we’ve entered the 4th industrial revolution, and healthcare + biopharma should be no exception.  The Xavier University AI Summit is a great event that brings together a range of relevant stakeholders with common focus on artificial intelligence (AI).

Bigfinite and NNE Partnership

Bigfinite and NNE announced a strategic partner program agreement to collaborate around accelerating digital transformation within manufacturing operations at the world's leading pharmaceutical and biotech manufacturers. 

Where are Pharma Companies in the Age of Artificial Intelligence?

They say good things come to those who wait; we say good things come to those who wait but only the things left by the visionaries before them.  The pharmaceutical industry has long been known to lag in the adoption of new technology due to strong regulations. Even though regulators have recently begun to open up to several new ‘big data’ or pharma 4.0 technologies - the question remains, if pharma companies are doing the same?  In 2016, the European Pharmacopoeia 9.0 in Chapter 5.21 announced that neural networks (NN) and support vector machines (SVM) are valid chemometric techniques for processing analytical data sets. 

Data Scientist 4.0 – Bridging the World of Manufacturing and Data

Since the announcement of the 4th Industrial Revolution in 2011, multitudes of emerging technologies have transpired around “Industry 4.0”. Technologies such as digital twins, Industrial Internet of Things (IIoT), and cyber-physical systems have come into the scene as core elements, providing the necessary ingredients for a paradigm shift in manufacturing. Technologies around predictive analytics and artificial intelligence are pioneering new approaches with many use cases including predictive maintenance, autonomous process optimization, and pattern recognition - used to identify potential failures in real-time. Because of this, data science is becoming an invaluable discipline for our industry in order to transform information into knowledge.